Ionis Pharmaceuticals IONS Unrealized Losses on Investments (Before Tax)
Unrealized Losses on Investments (Before Tax) at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: Ionis Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's unrealized losses on investments (before tax).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's unrealized losses on investments (before tax)?
- Ionis Pharmaceuticals (IONS) reported unrealized losses on investments (before tax) of $2.73M in Q1 2026.
- How has Ionis Pharmaceuticals's unrealized losses on investments (before tax) changed year-over-year?
- Ionis Pharmaceuticals's unrealized losses on investments (before tax) increased by 58.3% year-over-year, from $1.73M to $2.73M.
- What is the long-term trend for Ionis Pharmaceuticals's unrealized losses on investments (before tax)?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's unrealized losses on investments (before tax) has grown at a -51.1% compound annual growth rate (CAGR), from $4.31M to $246K.
- What does unrealized losses on investments (before tax) mean?
- The total paper loss on investment securities that have not yet been sold.
- How do you interpret unrealized losses on investments (before tax)?
- An increase suggests declining market value of the investment portfolio, often due to rising interest rates or credit concerns.
- How does unrealized losses on investments (before tax) compare across companies?
- Standard metric for assessing interest rate risk exposure in corporate investment portfolios.